Angiosarcomas and Other Sarcomas of Endothelial Origin

Hematology/Oncology Clinics of North America

Volumn 27, Issue 5, 2013, Pages 975-988

  Cioffi, Angela ^a   Reichert, Sonia ^a   Antonescu, Cristina R ^b   Maki, Robert G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiosarcoma; Epithelioid hemangioendothelioma; FLT4; Kaposi sarcoma; KDR; Organ transplant; Translocation; Vascular sarcoma; VEGF

Indexed keywords

ANGIOPOIETIN; ANTHRACYCLINE; BEVACIZUMAB; BLEOMYCIN; CELL NUCLEUS ANTIGEN; CISPLATIN; CYCLIN D; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPHRIN; G PROTEIN COUPLED RECEPTOR; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PAZOPANIB; PREDNISOLONE; RAPAMYCIN; RETINOID; SORAFENIB; VASCULOTROPIN INHIBITOR; VINBLASTINE; VINCRISTINE;

ANGIOGENESIS; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL DECISION MAKING; ELECTRON THERAPY; HEALTH CARE QUALITY; HEMANGIOENDOTHELIOMA; HUMAN; KAPOSI SARCOMA; LOCAL THERAPY; MITOSIS RATE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RADIATION INDUCED NEOPLASM; RECURRENCE RISK; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TREATMENT RESPONSE; VASCULAR TUMOR; WORLD HEALTH ORGANIZATION;

ANGIOSARCOMA; EPITHELIOID HEMANGIOENDOTHELIOMA; FLT4; KAPOSI SARCOMA; KDR; ORGAN TRANSPLANT; TRANSLOCATION; VASCULAR SARCOMA; VEGF;

HEMANGIOSARCOMA; HUMANS;

EID: 84884979947     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.07.005     Document Type: Review

References (84)

1. Brennan M.F., Antonescu C.R., Maki R.G. Management of soft tissue sarcoma 2013, Springer, New York.
2. Semeere A.S., Busakhala N., Martin J.N. Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings. Curr Opin Oncol 2012, 24(5):522-530.
3. Seinen J.M., Styring E., Verstappen V., et al. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol 2012, 19(8):2700-2706.
4. Contreras A.L., Punar M., Tamboli P., et al. Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol 2010, 41(6):832-837.
5. Malagon H.D., Valdez A.M., Moran C.A., et al. Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases. Am J Surg Pathol 2007, 31(9):1356-1362.
6. Modern soft tissue pathology: tumors and non-neoplastic conditions 2010, Cambridge University Press, Cambridge (UK). 1st edition. M. Miettinen (Ed.).
7. Lau K., Massad M., Pollak C., et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest 2011, 140(5):1312-1318.
8. Kovacic J.C., Moore J., Herbert A., et al. Endothelial progenitor cells, angioblasts, and angiogenesis-old terms reconsidered from a current perspective. Trends Cardiovasc Med 2008, 18(2):45-51.
9. Comen E., Norton L., Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 2011, 8(6):369-377.
10. Kim M.Y., Oskarsson T., Acharyya S., et al. Tumor self-seeding by circulating cancer cells. Cell 2009, 139(7):1315-1326.
11. Lipshutz G.S., Brennan T.V., Warren R.S. Thorotrast-induced liver neoplasia: a collective review. JAm Coll Surg 2002, 195(5):713-718.
12. Buchholz T.A., Theriault R.L., Niland J.C., et al. The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers. JClin Oncol 2006, 24(3):361-369.
13. Marion M.J., Boivin-Angele S. Vinyl chloride-specific mutations in humans and animals. IARC Sci Publ 1999, 150:315-324.
14. Elliott P., Kleinschmidt I. Angiosarcoma of the liver in Great Britain in proximity to vinyl chloride sites. Occup Environ Med 1997, 54(1):14-18.
15. Stewart F.W., Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1948, 1(1):64-81.
16. Giraldo G., Beth E., Coeur P., et al. Kaposi's sarcoma: a new model in the search for viruses associated with human malignancies. JNatl Cancer Inst 1972, 49(6):1495-1507.
17. Cai Q., Verma S.C., Lu J., et al. Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Advances in virus research 2010, vol. 78:87-142. Academic Press, London UK.
18. Chang Y., Cesarman E., Pessin M.S., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266(5192):1865-1869.
19. Russo J.J., Bohenzky R.A., Chien M.C., et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996, 93(25):14862-14867.
20. Dahlke C., Maul K., Christalla T., et al. AmicroRNA encoded by Kaposi sarcoma-associated herpesvirus promotes b-cell expansion invivo. PLoS One 2012, 7(11):e49435.
21. Cesarman E., Nador R.G., Bai F., et al. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. JVirol 1996, 70(11):8218-8223.
22. Mahmoud M., Allinson K.R., Zhai Z., et al. Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 2010, 106(8):1425-1433.
23. Krebs L.T., Starling C., Chervonsky A.V., et al. Notch1 activation in mice causes arteriovenous malformations phenocopied by ephrinB2 and EphB4 mutants. Genesis 2010, 48(3):146-150.
24. Urness L.D., Sorensen L.K., Li D.Y. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000, 26(3):328-331.
25. Rossi S., Fletcher C.D. Angiosarcoma arising in hemangioma/vascular malformation: report of four cases and review of the literature. Am J Surg Pathol 2002, 26(10):1319-1329.
26. McKay K.M., Doyle L.A., Lazar A.J., et al. Expression of ERG, an Ets family transcription factor, distinguishes cutaneous angiosarcoma from histological mimics. Histopathology 2012, 61(5):989-991.
27. Italiano A., Thomas R., Breen M., et al. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosomes Cancer 2012, 51(6):569-578.
28. Guo T., Zhang L., Chang N.E., et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 2011, 50(1):25-33.
29. Manner J., Radlwimmer B., Hohenberger P., et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 2010, 176(1):34-39.
30. Antonescu C.R., Yoshida A., Guo T., et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009, 69(18):7175-7179.
31. Tanas M.R., Sboner A., Oliveira A.M., et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011, 3(98):98ra82.
32. Errani C., Zhang L., Sung Y.S., et al. Anovel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011, 50(8):644-653.
33. Antonescu C.R., Le Loarer F., Mosquera J.M., et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 2013, 52(8):775-784.
34. Errani C., Sung Y.S., Zhang L., et al. Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet 2012, 205(1-2):12-17.
35. Nascimento A.F., Raut C.P., Fletcher C.D. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol 2008, 32(12):1896-1904.
36. Kaipainen A., Korhonen J., Mustonen T., et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995, 92(8):3566-3570.
37. Wang Y., Nakayama M., Pitulescu M.E., et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465(7297):483-486.
38. Wang H.U., Chen Z.F., Anderson D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998, 93(5):741-753.
39. Shin D., Garcia-Cardena G., Hayashi S., et al. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 2001, 230(2):139-150.
40. Gerety S.S., Wang H.U., Chen Z.F., et al. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999, 4(3):403-414.
41. Trombetta D., Magnusson L., von Steyern F.V., et al. Translocation t(7;19)(q22;q13)-a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma?. Cancer Genet 2011, 204(4):211-215.
42. Hornick J.L., Fletcher C.D. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 2011, 35(2):190-201.
43. Billings S.D., Folpe A.L., Weiss S.W. Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol 2003, 27(1):48-57.
44. Riva G., Luppi M., Barozzi P., et al. How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood 2012, 120(20):4150-4159.
45. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. NEngl J Med 2005, 352(13):1317-1323.
46. Monaco A.P. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009, 87(2):157-163.
47. Epstein J.B. Treatment of oral Kaposi sarcoma with intralesional vinblastine. Cancer 1993, 71(5):1722-1725.
48. Tucker S.B., Winkelmann R.K. Treatment of Kaposi sarcoma with vinblastine. Arch Dermatol 1976, 112(7):958-961.
49. Morgan E.A., Kozono D.E., Wang Q., et al. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol 2012, 19(12):3801-3808.
50. Pervaiz N., Colterjohn N., Farrokhyar F., et al. Asystematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008, 113(3):573-581.
51. Woll P.J., Reichardt P., Le Cesne A., et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012, 13(10):1045-1054.
52. Northfelt D.W., Dezube B.J., Thommes J.A., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. JClin Oncol 1998, 16(7):2445-2451.
53. Stewart S., Jablonowski H., Goebel F.D., et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. JClin Oncol 1998, 16(2):683-691.
54. Gill P.S., Wernz J., Scadden D.T., et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. JClin Oncol 1996, 14(8):2353-2364.
55. Cooley T., Henry D., Tonda M., et al. Arandomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 2007, 12(1):114-123.
56. Cianfrocca M., Lee S., Von Roenn J., et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010, 116(16):3969-3977.
57. Lim S.T., Tupule A., Espina B.M., et al. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2005, 103(2):417-421.
58. Nasti G., Errante D., Talamini R., et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. JClin Oncol 2000, 18(7):1550-1557.
59. Uldrick T.S., Wyvill K.M., Kumar P., et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. JClin Oncol 2012, 30(13):1476-1483.
60. Krown S.E., Roy D., Lee J.Y., et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. JAcquir Immune Defic Syndr 2012, 59(5):447-454.
61. Fata F., O'Reilly E., Ilson D., et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86(10):2034-2037.
62. Skubitz K.M., Haddad P.A. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005, 104(2):361-366.
63. Fury M.G., Antonescu C.R., Van Zee K.J., et al. A14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005, 11(3):241-247.
64. Edmonson J.H., Long H.J., Richardson R.L., et al. Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. Cancer Chemother Pharmacol 1985, 15(2):181-182.
65. Stacchiotti S., Palassini E., Sanfilippo R., et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 2012, 23(2):501-508.
66. Maki R.G., D'Adamo D.R., Keohan M.L., et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. JClin Oncol 2009, 27(19):3133-3140.
67. Ray-Coquard I., Italiano A., Bompas E., et al. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 2012, 17(2):260-266.
68. Chugh R., Wathen J.K., Maki R.G., et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. JClin Oncol 2009, 27(19):3148-3153.
69. Agulnik M., Yarber J.L., Okuno S.H., et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013, 24(1):257-263.
70. Mir O., Domont J., Cioffi A., et al. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer 2011, 47(4):515-519.
71. Stacchiotti S., Palassini E., Libertini M., et al. Sirolimus in advanced hemangioendothelioma. JClin Oncol 2013, 31(Suppl). [abstract: 10565].
72. Weitz J., Klimstra D.S., Cymes K., et al. Management of primary liver sarcomas. Cancer 2007, 109(7):1391-1396.
73. Bonaccorsi-Riani E., Lerut J.P. Liver transplantation and vascular tumours. Transpl Int 2010, 23(7):686-691.
74. Nudo C.G., Yoshida E.M., Bain V.G., et al. Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol 2008, 22(10):821-824.
75. Herbert S.P., Huisken J., Kim T.N., et al. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science 2009, 326(5950):294-298.
76. Kim Y.H., Hu H., Guevara-Gallardo S., et al. Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. Development 2008, 135(22):3755-3764.
77. Bridge G., Monteiro R., Henderson S., et al. The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis. Blood 2012, 120(25):5063-5072.
78. Cascone T., Heymach J.V. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. JClin Oncol 2012, 30(4):441-444.
79. Baselga J., Cortes J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 2012, 366(2):109-119.
80. Flaherty K.T., Robert C., Hersey P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. NEngl J Med 2012, 367(2):107-114.
81. Shimizu T., Tolcher A.W., Papadopoulos K.P., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012, 18(8):2316-2325.
82. Marshall V., Martro E., Labo N., et al. Kaposi sarcoma (KS)-associated herpesvirus microRNA sequence analysis and KS risk in a European AIDS-KS case control study. JInfect Dis 2010, 202(7):1126-1135.
83. Pfeffer S., Sewer A., Lagos-Quintana M., et al. Identification of microRNAs of the herpesvirus family. Nat Methods 2005, 2(4):269-276.
84. Italiano A., Chen C.L., Thomas R., et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 2012, 118(23):5878-5887.